Oncolytics biotech incorporated
ONCY 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
ONCY 近期報酬表現
0.93%
Oncolytics biotech incorporated
6.23%
同產業平均
1.02%
S&P500
與 ONCY 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
EXAS | Exact sciences corporation | 2 分 | 2 分 | 2 分 | 2 分 | 1 分 | |
TGTX | Tg therapeutics inc | 3 分 | 2 分 | 2 分 | 3 分 | 1 分 | |
TSBX | Turnstone biologics corp | - | 2 分 | 4 分 | 1 分 | 1 分 | |
TXG | 10x genomics inc | 2 分 | 1 分 | 1 分 | 3 分 | 1 分 | |
NVCR | Novocure ltd | 3 分 | 2 分 | 2 分 | 2 分 | 1 分 |
- EXAS Exact sciences corporation價值 2 分趨勢 2 分波段 2 分籌碼 2 分股利 1 分查看更多
ONCY 公司資訊
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company's primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.